Immunostimulatory colloidal delivery systems for cancer vaccines. 2006

Anne Saupe, and Warren McBurney, and Thomas Rades, and Sarah Hook
School of Pharmacy, University of Otago, PO Box 913, Dunedin, New Zealand. anne.saupe@stonebow.otago.ac.nz

Cancer vaccine delivery is a multidisciplinary scientific field that is currently undergoing rapid development. An important component of cancer vaccines is the development of novel vaccine delivery strategies, such as colloidal immunostimulatory delivery systems. The importance of formulation strategies for cancer vaccines can be explained by the poor immunogenicity of tumour antigens. Colloidal vaccine delivery systems modify the kinetics, body distribution, uptake and release of the vaccine. This review explores recent research that is directed towards more targeted treatments of cancer through to colloidal vaccine delivery systems. Widely investigated carrier systems include polymeric micro- and nanoparticles, liposomes, archaeal lipid liposomes (archaeosomes), immune-stimulating complexes and virus-like particles. These systems are evaluated in terms of their formulation techniques, immunological mechanisms of action as well as the potential and limitations of such colloidal systems in the field of cancer vaccines.

UI MeSH Term Description Entries
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D003102 Colloids Two-phase systems in which one is uniformly dispersed in another as particles small enough so they cannot be filtered or will not settle out. The dispersing or continuous phase or medium envelops the particles of the discontinuous phase. All three states of matter can form colloids among each other. Hydrocolloids,Colloid,Hydrocolloid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016503 Drug Delivery Systems Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity. Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug
D016882 ISCOMs A formulation for presenting an antigen to induce specific immunologic responses. It consists of an assembly of antigens in multimeric form. The assembly is attached to a matrix with a built-in adjuvant, saponin. ISCOMs induce strong serum antibody responses, and are used as highly immunogenic forms of subunit vaccines. Immunostimulating Complexes,ISCOM,Immuno-Stimulating Complexes,Complexes, Immuno-Stimulating,Complexes, Immunostimulating,Immuno Stimulating Complexes
D049329 Nanostructures Materials which have structured components with at least one dimension in the range of 1 to 100 nanometers. These include NANOCOMPOSITES; NANOPARTICLES; NANOTUBES; and NANOWIRES. Nanomaterials,Nanostructured Materials,Material, Nanostructured,Materials, Nanostructured,Nanomaterial,Nanostructure,Nanostructured Material
D019496 Cancer Vaccines Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced. Cancer Vaccine,Neoplasm Vaccines,Tumor Vaccine,Tumor Vaccines,Vaccines, Cancer,Vaccines, Neoplasm,Vaccines, Tumor,Vaccine, Cancer,Vaccine, Tumor

Related Publications

Anne Saupe, and Warren McBurney, and Thomas Rades, and Sarah Hook
January 2021, Frontiers in immunology,
Anne Saupe, and Warren McBurney, and Thomas Rades, and Sarah Hook
February 2011, Pharmaceutical research,
Anne Saupe, and Warren McBurney, and Thomas Rades, and Sarah Hook
January 2020, Current pharmaceutical design,
Anne Saupe, and Warren McBurney, and Thomas Rades, and Sarah Hook
January 2003, Journal of drug targeting,
Anne Saupe, and Warren McBurney, and Thomas Rades, and Sarah Hook
May 2024, Journal of controlled release : official journal of the Controlled Release Society,
Anne Saupe, and Warren McBurney, and Thomas Rades, and Sarah Hook
January 2005, Critical reviews in therapeutic drug carrier systems,
Anne Saupe, and Warren McBurney, and Thomas Rades, and Sarah Hook
January 2008, Human vaccines,
Anne Saupe, and Warren McBurney, and Thomas Rades, and Sarah Hook
November 2021, Molecules (Basel, Switzerland),
Anne Saupe, and Warren McBurney, and Thomas Rades, and Sarah Hook
February 2022, Pharmaceutics,
Anne Saupe, and Warren McBurney, and Thomas Rades, and Sarah Hook
January 2021, Vaccines,
Copied contents to your clipboard!